Showing 2641-2650 of 4063 results for "".
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/Nicox SA announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase, as well as the required two-week, follow-up period. Top-line results are expected to be announced in September 2021. “The Phase 2b Missis
- Gemini Therapeutics Announces Data From Ongoing Phase 2a Study in Patients with GA Secondary to Dry AMDhttps://modernod.com/news/gemini-therapeutics-announces-initial-data-from-its-ongoing-phase-2a-study-of-gem103-in-patients-with-geographic-atrophy-secondary-to-dry-amd/2479317/Gemini Therapeutics announced initial data from its phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant huma
- The Vision Council Releases Results of the 2020 Internet Influence Reporthttps://modernod.com/news/the-vision-council-releasese280afresults-of-the-2020-internet-influence-report/2479298/The Vision Council has released the results of the “Internet Influence Report.” Conducted in December 2020, the special interest consumer report examines the role of the Internet among consumers who recently purchased different types of eyewear. The Vision Council fielded
- Market Scope: Ophthalmic Laser Market Expected to Total $376.4 Million in 2021https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-376-4-million-in-2021/2479296/Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compound annual rate of 2.4 percent from 2021 to 2026, according to Market Scope estimates. Factor
- Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-cohort-1-of-oasis-phase-1-2a-trial-of-cls-ax-for-the-treatment-of-wet-amd/2479292/Clearside Biomedical announced positive safety results from Cohort 1 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in six patients (n=6) with neovascular age-rel
- Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/Nicox announced that more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi phase 2b blepharitis clinical trial. Topline results are expected to be announced during September 2021. “Blepharitis is a highly prevalent eye condition with frequent exac
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19https://modernod.com/news/gensight-biologics-provides-2021-operations-update-in-the-context-of-covid-19/2479212/GenSight Biologics provided an update on the impact of COVID-19 on its operations in 2021. “It has been slightly over a year since we had to adjust our operations to the COVID-19 situation and provided you with an update on our activities. Although conditions have improved in many regions,
- Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22https://modernod.com/news/prevent-blindness-declares-second-annual-inherited-retinal-disease-ird-genetic-testing-week-as-may-16-22/2479209/Prevent Blindness has declared the second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” as May 16-22, 2021. As part of this initiative, Prevent Blindness will be posting a series of educational graphics on its social media channels, including Facebook, Twitter, and Instagram.
- ReGenTree Announces Additional Results From ARISE-3 Trial Using RGN-259 for the Treatment of Dry Eyehttps://modernod.com/news/regentree-announces-additional-results-from-arise-3-using-rgn-259-for-the-treatment-of-dry-eye/2479211/ReGenTree, a U.S. joint venture company between GtreeBNT and RegeneRx, announced results of additional analysis of the phase 3 clinical trial, ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The company also pooled data from all three phase 3 clinical trials for dry eye. In A
- Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMDhttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-study-of-gem103-as-an-add-on-to-anti-vegf-therapy-for-the-treatment-of-wet-amd/2479205/Gemini Therapeutics announced the completion of enrollment in its phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atroph